Naruto Shimonishi
Kashihara-shi, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Extended Half-Life Recombinant Factor VIII Conjugated with Modifying Substances Does Not Affect Fibrin Clot Formation or Stability in Haemophilia A Blood Samples.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: March 30, 2026
Maternal-fetal transfer of emicizumab in a pregnant mouse model.
Journal: Blood advances
Published: December 04, 2025
Impact of Emicizumab on Coagulation Potential in Plasma From Healthy Women and Carriers of Haemophilia A During Late Pregnancy.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: November 19, 2025
Emicizumab enhances the ex vivo coagulant potential in plasma samples from patients with von Willebrand disease.
Journal: International journal of hematology
Published: August 20, 2025
Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response.
Journal: Thrombosis and haemostasis
Published: April 29, 2025
Insights from in vitro global assays on possible doses of concomitant hemostatic agents in the presence of NXT007 in hemophilia A.
Journal: Journal of thrombosis and haemostasis : JTH
Published: January 21, 2025
A clot waveform analysis-based system for differential diagnosis of prolonged activated partial thromboplastin time in plasma samples.
Journal: International journal of hematology
Published: May 23, 2024
The in vitro cross-reactivity and blood coagulation potential of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A.
Journal: International journal of hematology
Published: May 09, 2024
Factor X consumption attenuates the coagulation effect of emicizumab: a case of severe hemophilia A treated with emicizumab and factor VIII-bypassing agents.
Journal: International journal of hematology
Published: May 09, 2024
Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates.
Journal: Research and practice in thrombosis and haemostasis
Published: March 23, 2024
A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del).
Journal: Journal of thrombosis and haemostasis : JTH
Published: November 22, 2023
Last Updated: 09/26/2026